CD274 and gastric cancer: To date, only three molecular biomarkers have been demonstrated to predict responses to targeted therapies in GC [2]: human epidermal growth factor receptor 2-positive (HER2+) GC for trastuzumab and for trastuzumab deruxtecan, and microsatellite instability-high (MSI-H) and programmed death-ligand 1-positive (PD-L1+) GC for pembrolizumab.